New medium offers faster, cheaper drug-resistance detection

Article excerpt

A faster, cheaper method for detecting fidaxomicin resistance in Clostridioides difficile infections could accelerate treatment decisions for one of healthcare's stubborn bacterial challenges. Current screening methods are slow and costly, forcing clinicians to wait days for results while patients risk receiving ineffective antibiotics. Researchers have developed a new medium that speeds detection while cutting costs, potentially shortening the gap between infection and proper therapy. C. difficile, which causes severe diarrhea and can be life-threatening, increasingly develops resistance to fidaxomicin, a common first-line treatment. The innovation addresses a real clinical bottleneck: knowing quickly whether an infection will respond to standard antibiotics.